Dexcom Cash Flow Statement
DXCM / Health Care|15 years of annual SEC 10-K data (FY2011-FY2025)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 15 fiscal years. All figures from audited SEC 10-K filings.
Dexcom generated $1.4B in operating cash flow and $1.1B in free cash flow in FY2025. Free cash flow margin was 23.1% of revenue.
Based on SEC 10-K filings.
Key Data Points
- High earnings quality (cash-backed earnings)
- Strong return on equity: 26.4%
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | $836.3M | $576.2M | $541.5M | $549.7M | $216.9M | $549.7M | $101.1M | -$127.1M | -$57.6M | -$22.4M | -$29.8M | -$22.4M | -$29.8M | -$54.5M | -$44.7M |
| Depreciation & Amortization | $251.8M | $217.7M | $186.0M | $67.1M | $102.0M | $67.1M | $48.7M | $29.1M | $10.8M | $8.4M | $7.0M | $8.4M | $7.0M | $6.6M | $3.8M |
| Operating Cash Flow | $1.4B | $989.5M | $748.5M | $475.6M | $442.5M | $475.6M | $314.5M | $123.2M | $49.0M | $23.6M | $2.4M | $23.6M | $2.4M | -$33.1M | -$30.1M |
| Capital Expenditures | $363.5M | $358.8M | $236.6M | $199.0M | $389.2M | $199.0M | $180.0M | $67.1M | $33.3M | $16.2M | $7.9M | $16.2M | $7.9M | $9.5M | $8.0M |
| Free Cash Flow | $1.1B | $630.7M | $511.9M | $276.6M | $53.3M | $276.6M | $134.5M | $56.1M | $15.7M | $7.4M | -$5.5M | $7.4M | -$5.5M | -$42.6M | -$38.1M |
| Share Buybacks | $500.0M | $750.0M | $688.7M | $0 | $0 | $0 | $0 | $100.0M | - | - | - | - | - | - | - |
| FCF Margin | 23.1% | 15.6% | 14.1% | 14.4% | 2.2% | 14.4% | 9.1% | 5.4% | 11.0% | 6.4% | -7.5% | 15.7% | -18.6% | -42.6% | -49.9% |